Antibody-drug conjugates in acute myeloid leukaemia: more research needed
Mené sur 91 patients atteints d'une leucémie myéloïde aiguë réfractaire ou récidivante, cet essai de phase I/II détermine la dose maximale tolérée du pivékimab sunirine (un conjugué anticorps-médicament ciblant CD123) puis évalue son efficacité du point de vue du taux de réponse globale et du taux de rémission complète
In The Lancet Oncology, Naval G Daver and colleagues 1 report the results of a first-in-human, phase 1/2 dose-escalation and dose-expansion study evaluating the safety and antileukaemia activity of pivekimab sunirine (IMGN632) in patients with relapsed or refractory CD123-positive acute myeloid leukaemia aged 18 years or older. Pivekimab sunirine is a first-in-class antibody–drug conjugate comprising a high-affinity CD123 antibody conjugated to an alkyl-benzodiazepine. 2 The primary endpoints of the study were the maximum tolerated dose and recommended phase 2 dose.
The Lancet Oncology 2024